HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of ...

Q1 2025 Management View CEO David Dodd emphasized the company's commitment to advancing its portfolio, including GEO-CM04S1, ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

Fulcrum Therapeutics, Inc. ( NASDAQ: FULC) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Alex Sapir – President and Chief Executive Officer Alan Musso – Chief Financial Officer Iain Fraser – ...

Following clearance from the FDA, a phase 1/2 study will assess OBI-902 in Trop-2-overexpressing solid tumors, with plans for ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Lexeo Therapeutics, Inc.’s LXEO share price has surged by 9.41%, which has investors questioning if this is right time to ...

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to ...

Tresidder said his Melbourne-based firm has “a real focus” on biotech and life sciences. He sketched some of the ways brokers ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

Tharimmune, Inc., (NASDAQ:THAR) (”Tharimmune” or the “Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced ...